Immunic (IMUX)
(Delayed Data from NSDQ)
$1.27 USD
+0.03 (2.42%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $1.26 -0.01 (-0.79%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Price, Consensus and EPS Surprise
IMUX 1.27 +0.03(2.42%)
Will IMUX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IMUX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMUX
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade
IMUX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Other News for IMUX
Immunic to Participate in Industry and Scientific Conferences in June
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
Immunic, Inc. 2024 Q1 - Results - Earnings Call Presentation